News Roundup: MS

August 20, 2015
Mark L. Fuerst

We present findings from 3 recent studies concerning multiple sclerosis research and treatment.

The frequency of specific autoreactive antibodies is not higher among patients with multiple sclerosis (MS) than healthy people, suggesting that these antibodies are not associated with MS or disease progression. Long-term fingolimod therapy maintains a low rate of disease activity and sustains improved efficacy in MS patients who switched from interferon β-1a (IFNβ-1a). A younger age of onset of MS is associated with more impairment in information-processing speed in adults with pediatric-onset MS compared to those with adult-onset MS.